In detail, these trials consistently demonstrated the non-inferiority of SGLT-2 inhibitors relative to placebo [14,15,16,17], but the EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) and CANVAS (Canagliflozin Cardiovascular Assessment Study) trials unexpectedly showed that empagliflozin and canagliflozin were superior to placebo in lowering the risk for major adverse cardiovascular events [15,17]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.